AstraZeneca PLC (AZN.L) News| Reuters.com
Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,273.50GBp
28 Jun 2016
Change (% chg)

147.50p (+3.58%)
Prev Close
4,126.00p
Open
4,217.50p
Day's High
4,285.00p
Day's Low
4,174.00p
Volume
5,193,980
Avg. Vol
2,656,590
52-wk High
4,634.00p
52-wk Low
3,680.00p

Select another date:

Thu, Jun 23 2016

Photo

U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

LONDON/CHICAGO - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the nasal spray vaccine is not effective at preventing influenza.

UPDATE 3-U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

LONDON/CHICAGO, June 23 U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the nasal spray vaccine is not effective at preventing influenza.

UPDATE 2- U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

LONDON/CHICAGO, June 23 U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the nasal spray vaccine is not effective at preventing influenza.

UPDATE 1-AstraZeneca takes $80 mln hit as U.S. spurns nasal flu vaccine

LONDON, June 23 AstraZeneca said it would take an $80 million writedown on stocks of its flu vaccine Flumist Quadrivalent, which is sprayed into the nose, after U.S. health authorities decided they would not use the product.

BRIEF-AstraZeneca confirms CDC interim recommendation on flu vaccine

* Confirmed that ACIP center of CDC has provided interim recommendation on use of flumist quadrivalent live attenuated influenza vaccine Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

BRIEF-AstraZeneca names a head for its integrated cardio metabolic centre

* Christer Betsholtz appointed new head of Karolinska Institutet and AstraZeneca's integrated cardio metabolic centre Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

AstraZeneca sells rights to anesthetics for up to $770 million

LONDON AstraZeneca has sold the marketing rights to a portfolio of anesthetics for up to $770 million in the latest so-called externalization deal to raise funds for investment in new drugs.

UPDATE 1-AstraZeneca sells rights to anaesthetics for up to $770 mln

* Aspen shares jump 10 percent, AstraZeneca stock slips (Adds context on externalisation drive, market reaction)

BRIEF-Continental Investment, Harwood Capital evaluating possible offer for Source Bioscience

* Continental and Harwood capital in process of evaluating and preparing for possible offer for Source Bioscience Plc Source text for Eikon:

AstraZeneca sells EU, Latam gout drug rights to Gruenenthal

LONDON AstraZeneca has sold the European and Latin American rights to its new gout drug Zurampic to private German drugmaker Gruenenthal for up to $230 million, following a similar disposal of U.S. rights to the medicine.

Select another date: